| Year |
Citation |
Score |
| 2022 |
LoRusso P, Ratain MJ, Doi T, Rasco DW, de Jonge MJA, Moreno V, Carneiro BA, Devriese LA, Petrich A, Modi D, Morgan-Lappe S, Nuthalapati S, Motwani M, Dunbar M, Glasgow J, et al. Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study. Investigational New Drugs. PMID 35467243 DOI: 10.1007/s10637-022-01247-1 |
0.37 |
|
| 2020 |
Lemech C, Woodward N, Chan N, Mortimer J, Naumovski L, Nuthalapati S, Tong B, Jiang F, Ansell P, Ratajczak CK, Sachdev J. A first-in-human, phase 1, dose-escalation study of ABBV-176, an antibody-drug conjugate targeting the prolactin receptor, in patients with advanced solid tumors. Investigational New Drugs. PMID 32524319 DOI: 10.1007/s10637-020-00960-z |
0.338 |
|
| 2017 |
Nishikawa T, Matsumoto K, Tamura K, Yoshida H, Imai Y, Miyasaka A, Onoe T, Yamaguchi S, Shimizu C, Yonemori K, Shimoi T, Yunokawa M, Xiong H, Nuthalapati S, Hashiba H, et al. A Phase 1 Dose-Escalation Study of Single-Agent Veliparib in Japanese Patients with Advanced Solid Tumors. Cancer Science. PMID 28665051 DOI: 10.1111/cas.13307 |
0.325 |
|
| 2012 |
Nuthalapati S, Zhou Q, Guo P, Lv H, Cosenza S, Reddy MV, Reddy EP, Gallo JM. Preclinical pharmacokinetic and pharmacodynamic evaluation of novel anticancer agents, ON01910.Na (Rigosertib, Estybon™) and ON013105, for brain tumor chemotherapy. Pharmaceutical Research. 29: 2499-511. PMID 22678771 DOI: 10.1007/S11095-012-0780-Y |
0.321 |
|
| 2007 |
Zhou Q, Guo P, Wang X, Nuthalapati S, Gallo JM. Preclinical pharmacokinetic and pharmacodynamic evaluation of metronomic and conventional temozolomide dosing regimens. The Journal of Pharmacology and Experimental Therapeutics. 321: 265-75. PMID 17259446 DOI: 10.1124/Jpet.106.118265 |
0.32 |
|
| Show low-probability matches. |